What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Ronald M. Bukowski mainly focuses on Internal medicine, Renal cell carcinoma, Surgery, Oncology and Kidney cancer.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Endocrinology.
His studies deal with areas such as Kidney disease, Interferon alfa, Immunotherapy, Carcinoma and Metastasis as well as Renal cell carcinoma.
His Surgery research incorporates themes from Urology, Clinical trial, Nephrectomy and Hazard ratio.
His study focuses on the intersection of Kidney cancer and fields such as Clear cell renal cell carcinoma with connections in the field of Axitinib.
When carried out as part of a general Sunitinib research project, his work on Pazopanib is frequently linked to work in Temsirolimus, therefore connecting diverse disciplines of study.
His most cited work include:
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. (4612 citations)
- Sorafenib in advanced clear-cell renal-cell carcinoma. (4025 citations)
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (1731 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Renal cell carcinoma, Oncology, Surgery and Cancer research.
His research is interdisciplinary, bridging the disciplines of Gastroenterology and Internal medicine.
His Renal cell carcinoma study integrates concerns from other disciplines, such as Cancer, Carcinoma and Immunology.
His Oncology study combines topics from a wide range of disciplines, such as Targeted therapy, Clinical trial, Vascular endothelial growth factor and Disease.
He has included themes like Adverse effect, Nephrectomy and Urology in his Surgery study.
His work on Pazopanib as part of general Sunitinib study is frequently linked to Temsirolimus, therefore connecting diverse disciplines of science.
He most often published in these fields:
- Internal medicine (53.94%)
- Renal cell carcinoma (41.83%)
- Oncology (33.94%)
What were the highlights of his more recent work (between 2007-2020)?
- Internal medicine (53.94%)
- Renal cell carcinoma (41.83%)
- Oncology (33.94%)
In recent papers he was focusing on the following fields of study:
Ronald M. Bukowski spends much of his time researching Internal medicine, Renal cell carcinoma, Oncology, Sunitinib and Sorafenib.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Surgery.
His research in Surgery intersects with topics in Urology, Toxicity and Hazard ratio.
Ronald M. Bukowski combines subjects such as Cancer, Targeted therapy, Clinical trial, Vascular endothelial growth factor and Carcinoma with his study of Renal cell carcinoma.
The concepts of his Oncology study are interwoven with issues in Response Evaluation Criteria in Solid Tumors, Survival rate, Pathology, Nephrectomy and Survival analysis.
His work in the fields of Pazopanib overlaps with other areas such as Temsirolimus.
Between 2007 and 2020, his most popular works were:
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (1731 citations)
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study (1233 citations)
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (907 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Renal cell carcinoma, Oncology, Sunitinib and Surgery.
His Renal cell carcinoma research includes elements of Anorexia, First line treatment, Interferon, Nephrectomy and Immunotherapy.
Ronald M. Bukowski has researched Oncology in several fields, including Survival rate, Pathology, Cancer and Response Evaluation Criteria in Solid Tumors.
His research integrates issues of Urology, Toxicity, Myeloid-derived Suppressor Cell, Tyrosine-kinase inhibitor and Pharmacology in his study of Sunitinib.
Ronald M. Bukowski interconnects Gastroenterology, Clinical trial and Hazard ratio in the investigation of issues within Surgery.
Ronald M. Bukowski works mostly in the field of Kidney cancer, limiting it down to concerns involving Pazopanib and, occasionally, Everolimus.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
